NYSE$EW

Edwards Lifesciences Corp · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

Edwards Lifesciences reported Q4 2025 sales of $1.57B (+13.3%) with adjusted EPS of $0.58.

Sales grew 13.3% to $1.57 billion; TAVR sales rose 12% to $1.16 billion and TMTT sales exceeded $156 million (+40%). GAAP EPS was $0.11; adjusted EPS was $0.58.

  • Q4 sales $1.57B (+13%).
  • TAVR $1.16B; TMTT +40%.
  • Adjusted EPS $0.58.
  • 2026 constant-currency sales growth guide 8%–10%.

Headline financials

Total Revenue

$1.57B

Previous: $1.39B+13.3%
EPS (adj)

$0.58

Previous: $0.59-1.7%
Gross Profit Margin

78.1%

No prior period
SG&A Expenses

38.4%

No prior period
R&D Expenses

17.1%

No prior period
Operating Profit Margin

9.6%

No prior period
Effective Tax Rate

29.0%

No prior period
Net Income

$91.2M

Previous: $345M-73.6%
Operating Income

$151M

Previous: $313M-51.7%
Gross Profit

$1.23B

Previous: $1.09B+12.2%

Revenue & EPS history

Edwards Lifesciences · Revenue · Quarterly

$1.57B

Q4 2025+13.3%vs Q4 2024
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Edwards Lifesciences · $1.26B total across 3 segments · Q3 2023

  • Transcatheter Aortic Valve Replacement
    $961M+11.4%
  • Surgical Structural Heart
    $247M+12.2%
  • Transcatheter Mitral & Tricuspid
    $52.4M+76.4%

Forward guidance

The release discusses Edwards Lifesciences's outlook, including operating priorities, capital returns, and sector risks relevant to upcoming periods.

Tailwinds

  • Edwards Lifesciences cites execution on strategic priorities and demand trends in the release.
  • Capital allocation and balance-sheet actions support growth and shareholder returns.

Headwinds

  • Macro, pricing, and input-cost volatility could pressure margins.
  • One-time items and segment mix may affect quarter-to-quarter comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-1.3%

Avg return

Earnings day

-2.1%

Avg return

5 days after

-1.5%

Avg return

30 days after

50%

35 / 70 earnings

Positive

+11.6%

Q1 2017

Best reaction

-31.4%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.1%+1.9%+7.7%
Q4 2025+3.0%-1.5%+6.2%
Q3 2025-0.8%-0.8%+3.8%
Q2 2025+0.1%+4.1%-0.8%
Q1 2025+6.6%+8.3%+6.4%
Q4 2024+6.9%+7.4%-2.3%
Q3 2024-1.7%-1.8%-0.2%
Q2 2024-31.4%-26.8%-18.6%
Q1 2024-2.5%-4.4%-0.7%
Q4 2023+0.6%-1.2%+9.0%
Q3 2023-10.9%-11.5%-3.7%
Q2 2023-9.8%-10.5%-16.9%
Q1 2023-1.2%-0.3%-6.6%
Q4 2022+7.1%+8.0%+5.5%
Q3 2022-18.3%-16.3%-12.0%
Q2 2022-4.8%-3.2%-13.6%
Q1 2022-8.3%-11.7%-17.7%
Q4 2021-6.9%-0.3%+3.2%
Q3 2021-0.4%-1.2%-6.4%
Q2 2021+2.0%+4.2%+5.8%
Q1 2021+7.5%+10.0%+4.8%
Q4 2020-3.7%-5.3%-4.0%
Q3 2020-6.0%-7.5%+0.1%
Q2 2020+0.3%-0.6%+1.0%
Q1 2020+3.2%-1.6%+1.1%
Q4 2019-5.5%-2.7%-12.0%
Q3 2019+3.0%+6.8%+8.4%
Q2 2019+10.8%+9.7%+11.7%
Q1 2019-0.3%-1.2%-4.7%
Q4 2018-0.0%+0.8%+2.9%
Q3 2018-6.0%-6.1%-0.7%
Q2 2018-8.5%-8.2%-8.6%
Q1 2018-5.6%-5.8%+0.3%
Q4 2017+4.1%+0.4%+6.3%
Q3 2017-9.4%-10.7%-4.6%
Q2 2017+0.4%-0.6%-3.5%
Q1 2017+11.6%+12.0%+16.5%
Q4 2016-6.8%-6.6%-3.9%
Q3 2016-19.5%-17.8%-25.8%
Q2 2016+7.4%+7.5%+7.7%
Q1 2016+0.9%
Q4 2015+5.7%
Q3 2015+0.7%
Q2 2015+0.7%
Q1 2015-1.8%
Q4 2014+7.5%
Q3 2014+10.9%
Q2 2014+9.4%
Q1 2014+0.7%
Q4 2013+1.0%
Q3 2013-9.3%
Q2 2013+2.3%
Q1 2013-22.8%
Q4 2012-7.1%
Q3 2012-0.3%
Q2 2012+4.5%
Q4 2011-1.6%
Q1 2012+11.6%
Q3 2011-5.9%
Q2 2011-3.5%
Q4 2010+0.5%
Q1 2010+0.5%
Q1 2011-2.1%
Q4 2008-1.7%
Q1 2009-1.7%
Q3 2010+1.3%
Q3 2009+1.3%
Q2 2009+1.3%
Q2 2010+1.3%
Q4 2009+1.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro